Skip to main content
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel

James Davis CV

Associate Professor of Medicine
Medicine, General Internal Medicine
Office hours I see patients on Fridays 
Call 919-613-QUIT  
CV

Overview


Dr. James Davis is a practicing physician of Internal Medicine, and serves as the Medical Director for Duke Center for Smoking Cessation, Director of the Duke Smoking Cessation Program and Co-Director of the Duke-UNC Tobacco Treatment Specialist Credentialing Program.  His research focuses on development of new pharmaceutical treatments for smoking cessation.  He is principal investigator on several trials including a study on “adaptive” smoking cessation and several trials on new medications for smoking cessation. The new medications leverage more novel neurobiological mechanisms - NMDA receptor antagonism, nicotinic receptor antagonism, which impact addiction-based learning and cue response. Additionally, Dr. Davis serves as co-investigator on trials on lung cancer screening, e-cigarettes, minor nicotine alkaloids, imaging trials, lung function trials and others. Dr. Davis leads the Duke Smoke-Free Policy Initiative, is co-author on a national  tobacco dependence treatment guideline, and provides training in tobacco dependence treatment for the Duke School of Medicine, Duke Internal Medicine, Family Practice and Psychiatry residency programs.

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, General Internal Medicine, Medicine
Member of the Duke Cancer Institute · 2013 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published October 15, 2019
Vaping: Crisis or Lost Opportunity?
Published July 25, 2017
Do Filtered Cigarettes Lower the Risk of Lung Cancer?
Published August 13, 2014
From the Tobacco Fields to the Lab: DCI Faculty Tests 'Now'-Center Approach to Quitting Smoking

View All News

Recent Publications


Longitudinal Assessment of Communication With Patient-Reported Outcomes During Lung Cancer Screening.

Journal Article Chest · March 2025 BACKGROUND: Many organizations recommend clinicians use structured communication processes, referred to as shared decision-making, to improve patient-reported outcomes for patients considering lung cancer screening (LCS). RESEARCH QUESTION: Which component ... Full text Link to item Cite

Associations of Concordant and Shared Lung Cancer Screening Decision Making with Decisional Conflict: A Multi-Institution Cross-Sectional Analysis

Journal Article MDM Policy and Practice · January 1, 2025 Introduction. Many organizations recommend structured communication processes, including formal shared decision making (SDM), for patients undergoing lung cancer screening (LCS) using low-dose computed tomography (LDCT). We sought to understand if concorda ... Full text Cite

Use of low-dose varenicline in patients who do not tolerate standard-dose varenicline: A longitudinal case series

Journal Article Tobacco Prevention and Cessation · January 1, 2025 INTRODUCTION Although varenicline tartrate is the most effective monotherapy for smoking cessation, the standard-dose (1 mg twice daily) is associated with adverse events: gastrointestinal, sleep-related, and mood-related. Lower doses have demonstrated sim ... Full text Cite
View All Publications

Recent Grants


DELFI - Investigating the Clinical Utility of DELFI L301 Evaluation of Lung Cancer Screening

Clinical TrialPrincipal Investigator · Awarded by Delfi Diagnostics, Inc. · 2023 - 2028

CASCADE - Lung

Clinical TrialPrincipal Investigator · Awarded by Delfi Diagnostics, Inc. · 2022 - 2027

Comprehensive Research Program Development and Aerosol Acceptability PIL & Technology Comprehension Study

Clinical TrialPrincipal Investigator · Awarded by Predictably Human, Inc · 2021 - 2026

View All Grants